^
    Back
    Association details:
    Biomarker:KIT mutation
    Cancer:Prostate Cancer
    Drug:abiraterone acetate (CYP17A1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASCO-GU 2023
    Title:

    Comparison of ctDNA between African American and Caucasian patients with CRPC post abiraterone and/or enzalutamide.

    Published date:
    02/13/2023
    Excerpt:
    African Americans with CRPC post treatment with abiraterone and/or enzalutamide had a higher frequency of P/LP CDK12 and KIT mutations, which have both been shown to lead to aggressive clinical features and treatment resistance.
    DOI:
    10.1200/JCO.2023.41.6_suppl.35